Relationship between the urinary excretion mechanisms of drugs and their physicochemical properties

Journal of Pharmaceutical Sciences

Volumn 102, Issue 9, 2013, Pages 3294-3301

  Ito, Sumito ^a   Ando, Hirotaka ^b   Ose, Atsushi ^a   Kitamura, Yoshiaki ^b   Ando, Tomohiro ^a   Kusuhara, Hiroyuki ^a   Sugiyama, Yuichi ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b KYORIN PHARMACEUTICAL CO LTD   (Japan)

^c RIKEN   (Japan)

Author keywords

Physicochemical; Renal clearance; Renal reabsorption; Renal transport; Transporters

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 4; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; ORGANIC CATION TRANSPORTER 2;

ARTICLE; CORRELATIONAL STUDY; DISSOCIATION CONSTANT; DRUG ABSORPTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG PROTEIN BINDING; GLOMERULUS FILTRATION RATE; KIDNEY CLEARANCE; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; PKA; URINARY EXCRETION;

PHYSICOCHEMICAL; RENAL CLEARANCE; RENAL REABSORPTION; RENAL TRANSPORT; TRANSPORTERS;

CATION TRANSPORT PROTEINS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PHARMACEUTICAL PREPARATIONS;

EID: 84881610942     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23599     Document Type: Article

References (35)

1. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y. 1997. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73(2):147-171.
2. Rostami-Hodjegan A, Tucker GT. 2007. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6(2):140-148.
3. Watanabe T, Kusuhara H, Sugiyama Y. 2010. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. J Pharmacokinet Pharmacodyn 37(6):575-590.
4. Kusama M, Toshimoto K, Maeda K, Hirai Y, Imai S, Chiba K, Akiyama Y, Sugiyama Y. 2010. In silico classification of major clearance pathways of drugs with their physiochemical parameters. Drug Metab Dispos 38(8):1362-1370.
5. Wu CY, Benet LZ. 2005. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22(1):11-23.
6. Benet LZ, Broccatelli F, Oprea TI. 2011. BDDCS applied to over 900 drugs. AAPS J 13(4):519-547.
7. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12(3):413-420.
8. Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A. 2009. Physicochemical determinants of human renal clearance. J Med Chem 52(15):4844-4852.
9. Brunton LL, Lazo JS, Parker KL, Eds. 2005. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed., New York: McGraw-Hill Companies, Inc.
10. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. 2010. Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215-236.
11. Pitts RF. 1950. Acid-base regulation by the kidneys. Am J Med 9(3):356-372.
12. Brodie BB, Hogben CA. 1957. Some physico-chemical factors in drug action. J Pharm Pharmacol 9(6):345-380.
13. Kusuhara H, Sugiyama Y. 2009. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet 24(1):37-52.
14. Masereeuw R, Russel FG. 2010. Therapeutic implications of renal anionic drug transporters. Pharmacol Ther 126(2):200-216.
15. Wright SH, Dantzler WH. 2004. Molecular and cellular physiology of renal organic cation and anion transport. Physiol Rev 84(3):987-1049.
16. Inui KI, Masuda S, Saito H. 2000. Cellular and molecular aspects of drug transport in the kidney. Kidney Int 58(3):944-958.
17. Fujita T, Urban TJ, Leabman MK, Fujita K, Giacomini KM. 2006. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci 95(1):25-36.
18. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB. 1986. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47(3):381-389.
19. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. 1998. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95(26):15665-15670.
20. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P. 1997. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57(16):3537-3547.
21. Ito S, Kusuhara H, Kuroiwa Y, Wu C, Moriyama Y, Inoue K, Kondo T, Yuasa H, Nakayama H, Horita S, Sugiyama Y. 2010. Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther 333(1):341-350.
22. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. 2005. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 102(50):17923-17928.
23. +/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 17(8):2127-2135.
24. Watanabe T, Kusuhara H, Debori Y, Maeda K, Kondo T, Nakayama H, Horita S, Ogilvie BW, Parkinson A, Hu Z, Sugiyama Y. 2011. Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos 39(6):1031-1038.
25. Nakamura T, Yoshida K, Yabuuchi H, Maeda T, Tamai I. 2008. Functional characterization of ergothioneine transport by rat organic cation/carnitine transporter Octn1 (slc22a4). Biol Pharm Bull 31(8):1580-1584.
26. Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, Sai Y, Tsuji A. 1998. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 273(32):20378-20382.
27. Okabe M, Szakacs G, Reimers MA, Suzuki T, Hall MD, Abe T, Weinstein JN, Gottesman MM. 2008. Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 7(9):3081-3091.
28. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A. 1999. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): Its pharmacological and toxicological relevance. J Pharmacol Exp Ther 291(2):778-784.
29. Kato S, Kato Y, Nakamura T, Sugiura T, Kubo Y, Deguchi Y, Tsuji A. 2009. Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. Biopharm Drug Dispos 30(9):495-507.
30. Huwyler J, Fricker G, Torok M, Schneider M, Drewe J. 1997. Transport of clonidine across cultured brain microvessel endothelial cells. J Pharmacol Exp Ther 282(1):81-85.
31. Okura T, Ito R, Ishiguro N, Tamai I, Deguchi Y. 2007. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci 80(17):1564-1571.
32. Henthorn TK, Liu Y, Mahapatro M, Ng KY. 1999. Active transport of fentanyl by the blood-brain barrier. J Pharmacol Exp Ther 289(2):1084-1089.
33. Ito S, Kusuhara H, Yokochi M, Toyoshima J, Inoue K, Yuasa H, Sugiyama Y. 2012. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther 340(2):393-403.
34. Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, Inoue K, Yuasa H, Sugiyama Y. 2011. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 89(6):837-844.
35. Yonezawa A, Inui K. 2011. Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Br J Pharmacol 164(7):1817-1825.